Efficacy and Safety of Autologous Bone Marrow-derived Mesenchymal Stem Cell Treatment in Patients With Amyotrophic Lateral Sclerosis

Seung Hyun Kim, Jin Young Paek, Hee Kyung Park, Mi‐Ran Choi, Hyun Soo Yoon, Kyung Suk Kim, Seung Hyun Kim

Journal of the Korean Neurological Association · 2009 · 11 citations · 20 references

Concepts

Abstract

c Background: This study was performed to investigate the efficacy and safety of intrathecal autologous bone marrow- derived mesenchymal stem cells (MSCs) treatment for patients with ALS. Methods: After a lead-in period for 3 months, 22 patients were treated with MSCs twice at an interval of 1 month. After initial MSCs injection, all patients were followed up for 3 months and their disease course, clinical characteristics were assessed. Disease status of patients were analyzed with ALS functional rating scale-revised (ALSFRS-R) for primary outcome measure, and additional clinical findings after treatment were all collected for secondary outcome measure and safety. Age and disease-duration matched patients with ALS were selected as a control group. Results: During the follow-up period, MSCs treatment yielded a significant lesser change of ALSFRS-R score, compared to control group (1.54 vs 3.56, p<0.01). Moreover, the slop of decline of ALSFRS-R was significantly lower during the follow-up period, compared to the lead-in period in MSCs treatment group (2.68 vs 1.54, p=0.04), whereas the slopes during the two periods were not different in the control group (3.15 vs 3.56, p=0.37). MSCs treatment was well tolerated except for occurrences of transient headache, low back pain, and myalgia. Conclusions: Our results show that intrathecal MSCs injection can slow disease progression and might be used as a disease modifying modality as an alternative treatment choice in patients with ALS. J Korean Neurol Assoc 27(2):163-169, 2009

References

20